GPT and Recurrent upper respiratory tract infections: Among all subjects, seven (3.68%) mild adverse events were reported, including upper respiratory tract infection (n = 3), diarrhea (n = 1), elevated BUN concentration at Day 30 (n = 2), and elevated ALT and AST (n = 1).